to Frank. take few to the I'd next Thanks, regards update to we've minutes commercialization like outline what last our since plan. with accomplished our
positive. impact Effectiveness trial. CEA our to evaluates the ratio cost CEA economic have years its First, which describes quality and market initial observed life data relates incremental life as budget years, reduction for gain. year adjusted with on or the health AXc our model a health the an and treat variables, controlled adjusted pivotal time economic it impact Through an CEA greater impact cost intervention quality with or model long-term to Analysis for we from effectiveness model costs outcome I'm BT-XXX associated report The greater including the life over that to access, from And pleased and intent model, Comparative other randomized both using developed population of were was lower the our results lifetime horizon.
of effectiveness pay that And willingness a analysis a health as intervention. represent cost. as the such gains suggests and threshold at lower differently a said the BT-XXX resources. healthcare incremental achieves to is dominant ratio to it defined is cost means Its that this good additional below use considered is So,
our making evaluate to healthcare input they Competitive and are one their excited Effectiveness an for to important and value systems by about to payers. relative treatments society. importance add decision often payer Analyses component benefits since used And national these believe initial the to results, we're offer of we proposition
hospital model. which and heavily the and a such of Using one complications ER to demonstrates CEA, [indiscernible] years. new a associated costs and intent a we've inputs a costs, within cost population cost new budgetary first usually results treat weighing shorter with the the evaluates treatment costs And savings budget term impact five pharmacotherapy the potential to Shorter impact direct timeframe, see of model, from the in as two the also treatment impact budget years. the in developed to visits the about more initial
while Care model dossier. to Next, for our data also all of feed publication initiating Physicians ultimately we our our economic will National Association research. pricing Managed plan submit This health
we last making, elements products The and of BT-XXX the along both X December, the payers. study voting with The data value unmet for with members, value Now, type research. and burden coverage a our tested proposition and the payer blinded very story let value prior with current tested needs BT-XXX the to chairs treatment decision In for well since included current this information. the is test of were is research the me medical. feedback for in-line share Participants with clinical of some a payers conducted committees review story landscape, diabetes, or update. pharmacy of co-chairs
in along further this overall pre-authorization will proposition the And undergoing story value health payer over refine position our in few treat our with commence ahead we intent is of population. exchange to to research model us with element value results we of our and launch. are from economic meaningful findings related final April an The testing information and believe to to beginning payers with allow now next payers excellent in our meetings months the
payer another upon financial decision be engagement conducted coverage including role discussion. clinical and patient February play which with understand might tested could outcomes several in value study based we agreements agreements study, variables research makers messaging payer We to this Beyond targets. in structured the metrics,
to contracting BT-XXX’s Study profile pricing negotiations to As and indeed target important prior results. overall trial payer suggest guide to in yield positively and be product value-based conclusions payers reactive pivotal that important agreements insights will studies, our strategy. the and
priority, So, provider patient while is more a to adoption. market on take strong our it does focus access drive and
fit product recently follow-up clinician recognized patient it benefits will be visits journey into as is as patient be Our since would the provider treated confirms a to intended as the and be case prescription drug. BT-XXX work with workflows completed whose of
to of our it, we and ability by awareness this of to supporting fulfillment and of What aim of patients. our And adherence have them for prescription both evidence expanding action. is treatment the one, and publication and the this to mechanism its made nature And investigational digital to educating the keep therapy. time we inherent strategy in body raising therapy, the continue digital to and podium efforts more and delivery two, progress providers is to underlying simple expedite communicate therapy track investigational and science unique which novel BT-XXX
with published for Annual this a Dr. press to of X year. picking XX-day clinical as tremendous March study primary XXX than follow-up And Meeting, a year, publication trial plan, data the American publication delivered clinical on from XX College for up of headlines. noted, which our the poster submit we last our day results investigator presentation Marc principal the expect to at pivotal regards Bonaca, our endpoint with our more to Frank As Gartner's outlets BT-XXX trials Cardiology's
update an targeted claims market strategy. dominant X with provide to laid patients which plan map by we like informed quarter on our out network health regionally payers. would integrated a providers uncontrolled concentration type that go the I highest Finally, approximately XX overlap to delivery in to XX Last patient diabetes systems, of or analysis
launch endocrinologists, a initial up efforts. force further of is deployed targeted XX% a by strong of in sized this be of reasonable cohort, X% this this target that about set patient about indicates with believe a analysis mass we geographies. these that in of the patients this sales segmentation our provider to makes can And providers modestly key Further group one-third focusing deeper reveals of reached which about support group made
us prioritized data. map This a for on based of provides areas the view initial the
of profiles readiness health system targeted to and focused acquired geographies. champions BT-XXX identifying systems to health characterize recently in have list while key We and their also consider wide, evaluate these our systems of
pre-launch sharing make quarter. next to additional progress on continue updates we to preparations look and forward Overall, I
Chief our Officer, our financial Heinen, results. Mark? now Financial Mark will year-end review
